In male ApoE−/− mice receiving a western diet, Metoprolol treatment was not associated with changes in total plasma cholesterol levels compared with control. In the same model, Metoprolol significantly decreased thoracic aortic atherosclerotic plaque area compared with saline. In male large white pigs subjected to coronary occlusion and reperfusion, the pooled cohort showed lower infarct size relative to the area at risk with Metoprolol than with vehicle, irrespective of ischemia duration. In mice subjected to coronary artery occlusion and reperfusion, Metoprolol administered before reperfusion reduced infarct size normalized to the area at risk compared with vehicle. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Metoprolol and plasma cholesterol in ApoE−/− mice
Animal study · Male ApoE−/− mice (Taconic Transgenic Models Strain B6.129P2-Apoetm1Unc/N11 Taconic, Denmark), 6 weeks of age [1]
Male ApoE−/− mice receiving a western diet were treated with Metoprolol at 2.5 mg/kg per hour through subcutaneously implanted minipumps. Treatment was not associated with changes in total plasma cholesterol levels compared with control.
Conditions shared by the study groups
- Route
- minipumps were implanted subcutaneously on the back of the mouse
- Treatment course
- Eleven weeks of metoprolol treatment
- Metoprolol 2.5 mg/kg per hour
- Model: Male ApoE−/− mice (Taconic Transgenic Models Strain B6.129P2-Apoetm1Unc/N11 Taconic, Denmark), 6 weeks of age
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Metoprolol
The paper names Metoprolol without stating the salt or form; not verified as the tartrate form supplied as A11713. No dose conversion or lot validation.
2. Methods > 2.2. Study I: Dose-Finding > 2.2.1. Experimental Design (S7); 2. Methods > 2.3. Study II: Effects on Atherosclerosis > 2.3.1. Experimental Design (S11, S12, S13); 3. Results > 3.2. Study II: Effects on Atherosclerosis > 3.2.1. Metoprolol Reduced Atherosclerotic Plaque Area (S54); 3. Results > 3.2. Study II: Effects on Atherosclerosis > 3.2.3. Total Cholesterol (S58)
total plasma cholesterol levels: total plasma cholesterol levels; comparator: Control (C, n = 12) — 3. Results > 3.2. Study II: Effects on Atherosclerosis > 3.2.3. Total Cholesterol (S58)
Metoprolol 2.5 mg/kg per hour · 2. Methods > 2.2. Study I: Dose-Finding > 2.2.1. Experimental Design (S7); 2. Methods > 2.3. Study II: Effects on Atherosclerosis > 2.3.1. Experimental Design (S11, S13); 3. Results > 3.2. Study II: Effects on Atherosclerosis > 3.2.1. Metoprolol Reduced Atherosclerotic Plaque Area (S54); 3. Results > 3.2. Study II: Effects on Atherosclerosis > 3.2.3. Total Cholesterol (S58)
Metoprolol and infarct size in pigs
Animal study · 3-month-old male large white pigs weighing 30–35 kg [2]
Male large white pigs subjected to left anterior descending occlusion and reperfusion received intravenous Metoprolol at 0.75 mg/kg or vehicle. In the pooled cohort, infarct size relative to the area at risk was lower with Metoprolol than with vehicle, irrespective of ischemia duration.
Conditions shared by the study groups
- Route
- i.v.
- Treatment course
- 20 min after ischemia onset
- Metoprolol 0.75 mg/kg
- Model: 3-month-old male large white pigs weighing 30–35 kg
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Metoprolol
The paper names Metoprolol without stating the salt or form; not verified as the tartrate form supplied as A11713. No dose conversion or lot validation.
Methods > Study design (S4, S10, S11, S16, S17, S18); Methods > Pig model of STEMI (ischemia–reperfusion (I/R) protocol) (S29, S30); Methods > Arterial enhanced MDCT protocol and AAR quantification (S38); Methods > CMR protocol and analysis (S45); Fig. 4 legend (S118, S120); Table 2 (T2.h1, T2.h2, T2.r6)
Infarct size as % of the AAR (area at risk) at 7-day CMR follow-up: Infarct size as % of the AAR (area at risk) at 7-day CMR follow-up; comparator: i.v. vehicle (0.75 ml/kg saline) — Fig. 4 legend (S118); Table 2 (T2.h1, T2.h2, T2.r6)
Metoprolol 0.75 mg/kg · Methods > Study design (S10, S11); Table 2 (T2.h1, T2.h2, T2.r6)
Metoprolol and infarct size in mice
Animal study · mice subjected to ischaemia–reperfusion; n = 10 for each condition [3]
Mice subjected to coronary artery occlusion and reperfusion received a single intravenous Metoprolol bolus at 12.5 mg/kg before reperfusion. Infarct size normalized to the area at risk was smaller than in vehicle-treated mice.
Conditions shared by the study groups
- Route
- i.v.; through the retro-orbital sinus
- Treatment course
- a single bolus; 10 min before reperfusion (35 min after ischaemia onset)
- Vehicle
- 0.9% NaCl
- Metoprolol 12.5 mg/kg
- Model: mice subjected to ischaemia–reperfusion; n = 10 for each condition
Methods and source locations
Compound reported in the paper: Metoprolol
The paper names Metoprolol without stating the salt or form; not verified as the tartrate form supplied as A11713. No dose conversion or lot validation.
Results > Metoprolol, but not atenolol or propranolol, limits myocardial infarct size (S4, S5, S7, S9, S10); Figure 1 legend (S60, S63)
At 24 h post-reperfusion, mice were euthanized, and area at risk (AAR)-normalized IS was calculated.: At 24 h post-reperfusion, mice were euthanized, and area at risk (AAR)-normalized IS was calculated.; comparator: vehicle-treated mice — Results > Metoprolol, but not atenolol or propranolol, limits myocardial infarct size (S9, S10)
Metoprolol 12.5 mg/kg · Results > Metoprolol, but not atenolol or propranolol, limits myocardial infarct size (S5, S7, S10)
Metoprolol and aortic plaque area in ApoE−/− mice
Animal study · Male ApoE−/− mice (Taconic Transgenic Models Strain B6.129P2-Apoetm1Unc/N11 Taconic, Denmark), 6 weeks of age [1]
Male ApoE−/− mice receiving a western diet were treated with Metoprolol at 2.5 mg/kg per hour through subcutaneously implanted minipumps. Metoprolol significantly decreased thoracic aortic atherosclerotic plaque area compared with saline.
Conditions shared by the study groups
- Route
- minipumps were implanted subcutaneously on the back of the mouse
- Treatment course
- Eleven weeks of metoprolol treatment
- Metoprolol 2.5 mg/kg per hour
- Model: Male ApoE−/− mice (Taconic Transgenic Models Strain B6.129P2-Apoetm1Unc/N11 Taconic, Denmark), 6 weeks of age
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Metoprolol
The paper names Metoprolol without stating the salt or form; not verified as the tartrate form supplied as A11713. No dose conversion or lot validation.
2. Methods > 2.2. Study I: Dose-Finding > 2.2.1. Experimental Design (S7); 2. Methods > 2.3. Study II: Effects on Atherosclerosis > 2.3.1. Experimental Design (S11, S12, S13); 2. Methods > 2.4. Quantification of Atherosclerosis and Immunohistochemistry > 2.4.1. En Face Quantification of Thoracic Aorta (S21, S24); 3. Results > 3.2. Study II: Effects on Atherosclerosis > 3.2.1. Metoprolol Reduced Atherosclerotic Plaque Area (S54)
plaque area was calculated as the percentage of the total vessel area covered with lesions: plaque area was calculated as the percentage of the total vessel area covered with lesions; comparator: Control (C, n = 12) — 2. Methods > 2.4. Quantification of Atherosclerosis and Immunohistochemistry > 2.4.1. En Face Quantification of Thoracic Aorta (S24); 3. Results > 3.2. Study II: Effects on Atherosclerosis > 3.2.1. Metoprolol Reduced Atherosclerotic Plaque Area (S54)
Metoprolol 2.5 mg/kg per hour · 2. Methods > 2.2. Study I: Dose-Finding > 2.2.1. Experimental Design (S7); 2. Methods > 2.3. Study II: Effects on Atherosclerosis > 2.3.1. Experimental Design (S11, S13); 3. Results > 3.2. Study II: Effects on Atherosclerosis > 3.2.1. Metoprolol Reduced Atherosclerotic Plaque Area (S54)